Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
164.18
-0.64 (-0.39%)
Streaming Delayed Price
Updated: 2:58 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
April 08, 2024
From
Johnson & Johnson
Via
Business Wire
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
April 08, 2024
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend
Via
MarketBeat
Johnson & Johnson to Acquire Shockwave Medical
April 05, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
April 04, 2024
From
Johnson & Johnson
Via
Business Wire
Bev Jennings selected as VIP Speaker at Global Women Thrive Summit 2024
March 16, 2024
The presentation is virtual and live in-person as part of a collaboration with the WBENC Amplify Conference in Denver, COJACKSONVILLE, Fla. & DENVER - March 16, 2024 - PRLog -- Bev Jennings, a VIP...
Via
PRLog
Topics
Supply Chain
Exposures
Supply Chain
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
April 02, 2024
From
Johnson & Johnson
Via
Business Wire
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
March 24, 2024
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The Next Great Biotech Boom Has Arrived
March 19, 2024
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
March 11, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Completes Acquisition of Ambrx
March 07, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
February 14, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
February 12, 2024
From
Johnson & Johnson
Via
Business Wire
Verizon, Walgreens, 3M: 3 high-yield Dow stocks to buy now?
February 05, 2024
Dow's high-yielding trio, Verizon, Walgreens, and 3M face challenges, which are reflected in their stock-price declines.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
February 02, 2024
From
Johnson & Johnson
Via
Business Wire
4 med tech stocks with improving prognosis for 2024
January 31, 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025.
Via
MarketBeat
Exposures
COVID-19
Abbott Laboratories on track for new highs in 2024
January 25, 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.
Via
MarketBeat
Exposures
COVID-19
Intuitive Surgical’s post-earnings dip is a healthy time to buy
January 25, 2024
Intuitive Surgical had a solid quarter, but strength was expected, and the stock sold off; a healthy correction is good, but will investors buy the dip?
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Johnson & Johnson's stock price is at a critical turning point
January 23, 2024
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
3 personal care stocks that smell like good earnings plays
January 23, 2024
Management remarks about how they plan to use technology to drive growth could matter just as much as near-term financials for these personal care companies.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
January 23, 2024
From
Johnson & Johnson
Via
Business Wire
3 undervalued stocks: Is now the right time to buy?
January 22, 2024
WK Kellogg, Newmont, and WEC Energy Group have upside potential as undervalued stocks, although each is navigating challenges that pushed valuations lower.
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
January 08, 2024
From
Johnson & Johnson
Via
Business Wire
Are defensive sectors ready to outshine growth in 2024?
January 06, 2024
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.
Via
MarketBeat
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
January 02, 2024
From
Johnson & Johnson
Via
Business Wire
Asana sold the rip. Is it time to buy the dip?
December 12, 2023
Asana stock plunged as investors sold the news on its bullish earnings report, but with the company raising guidance, it may be time for investors buy the dip -
Via
MarketBeat
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
December 11, 2023
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 07, 2023
From
Johnson & Johnson
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.